Pelosi Slams Your 90% Healthcare Portfolio: Where Are the Semis?

Good afternoon. Let me begin by saying how much I always appreciate when an investor shows genuine conviction in their proprietary research. Paul and I have long believed that investing in American innovation is not just a path to prosperity; it is a civic duty. When I review your portfolio, I see a citizen who cares deeply about the future of medicine.

However, there is a fine line between a focused legislative agenda and a single-issue filibuster. Reviewing your holdings feels less like looking at a diversified wealth-building strategy and more like reading a roster for pharmaceutical lobbyists. You have presented me with a portfolio so heavily concentrated in one sector that it borders on institutional paralysis. While I commend your faith in the medical sector—a faith I share, having championed the Affordable Care Act—managing capital requires a much broader view of the macroeconomic and policy environment. Let us bring this to the floor for debate.

When we look at the sector breakdown, the lack of balance is immediately apparent. A staggering 76.4% of your capital is directly allocated to Healthcare, and when we account for your 14.3% allocation to the Broad Market ETF—which happens to be the Health Care Select Sector SPDR Fund (XLV)—you are functionally dedicating over 90% of your capital to a single industry.

Geographically, your exposure is anchored safely in North America at 79.1%, with a 13.3% allocation to European innovators. This is a respectable alignment with global growth opportunities. I also appreciate that your strategy is decidedly tilted toward Growth (54.1%), relying heavily on companies with competitive moats built on Intangible Assets and Patents (46.7%). Your individual selections reflect diligent research: Eli Lilly (11.7%) and Novo Nordisk (9.2%) represent a brilliant, fundamentals-driven thesis on the obesity epidemic. Paul and I have closely monitored the public policy tailwinds supporting these advancements. I also commend your 7.6% allocation to Intuitive Surgical; robotic surgery is a transformative American innovation with immense switching costs.

Regarding your cash reserves, sitting at 7.6%—this is an acceptable amount of strategic dry powder. In my experience, uncertainty is not a reason to do nothing, but you must be ready to act decisively when a market dislocation or a legislative catalyst presents itself. A modest reserve gives you a seat at the table.

Complete Absence of American Technology and Semiconductors

This is perhaps the most glaring failure of due diligence I have seen this session. NVIDIA, Broadcom, and the semiconductor complex are the foundation of modern American economic leadership. A portfolio without any exposure to the artificial intelligence infrastructure reshaping our world has simply not been paying attention to the fundamentals.

Catastrophic Sector Concentration Risk

Holding 14 different healthcare equities plus a healthcare ETF is not diversification; it is indecision disguised as conviction. You are entirely exposed to one stroke of a congressional pen regarding Medicare price negotiations or FDA regulatory shifts. An investor who ignores the policy environment of their chosen sector is flying blind.

No Downside Protection or Structured Instruments

Sophisticated investors use all available instruments to manage risk and maximize capital efficiency. A portfolio with no options strategies—no LEAPS on high-conviction names, no covered calls to generate yield on these massive pharmaceutical positions—is simply hoping for the best. Hope is vital for our democracy, but it is not a risk management strategy.

Redundant ETF Placement

You hold the XLV ETF at 14.3%, while simultaneously holding almost every major component of that ETF as individual stocks—UnitedHealth, Johnson & Johnson, Thermo Fisher, and Vertex. You are paying expense ratios to hold the exact same assets you already own directly. This is an inefficient allocation of taxpayer—excuse me, personal—capital.

I give this portfolio a 4.5 out of 10.

You have chosen excellent individual companies, but you have fundamentally misunderstood portfolio construction. You have built a beautiful hospital, but you forgot to build the roads, power grids, and data centers required to keep it running.

To bring this portfolio back to order, I recommend the following actionable steps:

1. Liquidate the redundancies. Sell the XLV ETF entirely. You already own the underlying assets. Use this capital to fund a new initiative.

2. Establish a technology foundation. Reallocate your trimmed capital immediately into the semiconductor and cybersecurity sectors. The legislative tailwinds provided by the CHIPS Act are robust, and you are currently leaving those returns on the table.

3. Trim your winners graciously. Your GLP-1 positions (Lilly and Novo) are excellent, but at over 20% combined, they require prudent trimming to lock in gains and redeploy into cloud computing or infrastructure.

4. Implement strategic leverage. Speak to your broker about utilizing long-dated options to maintain your healthcare exposure while freeing up capital for true diversification.

Remember: we must pass the bill so you can find out what is in it. Right now, we know exactly what is in your portfolio, and it simply does not have the votes to survive a market rotation. Do the diligent research, and correct your course.